leflunomide has been researched along with Granulomatosis, Wegener's in 8 studies
Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.
leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.
Excerpt | Relevance | Reference |
---|---|---|
"LEF at a dosage of 30 mg/day appears to be effective in the prevention of major relapses in WG, however, this is associated with an increased frequency of adverse events." | 2.73 | Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis. ( de Groot, K; Gross, WL; Hellmich, B; Iking-Konert, C; Manger, K; Metzler, C; Miehle, N; Reinhold-Keller, E, 2007) |
"Leflunomide treatment was initiated at 20 mg/day and increased to 30 mg/day after 12 weeks and, in patients with partial remission, to 40 mg/day after 24 weeks." | 2.71 | Maintenance of remission with leflunomide in Wegener's granulomatosis. ( Fink, C; Gross, WL; Lamprecht, P; Metzler, C; Reinhold-Keller, E, 2004) |
"In the past, recommendations for the treatment of Wegener's granulomatosis were primarily based on findings reported from open-label clinical trials." | 2.43 | Advances in the therapy of Wegener's granulomatosis. ( Gross, WL; Hellmich, B; Lamprecht, P, 2006) |
"Extensive Wegener's granulomatosis (WG) is treated by glucocorticosteroids (GC) and cyclophosphamide (CYC)." | 1.34 | Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide. ( Fritz, J; Henes, JC; Horger, M; Kanz, L; Klein, R; Koch, S; Koetter, I; Risler, T, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 6 (75.00) | 29.6817 |
2010's | 2 (25.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Lee, JJY | 1 |
Alsaleem, A | 1 |
Chiang, GPK | 1 |
Limenis, E | 1 |
Sontichai, W | 1 |
Yeung, RSM | 1 |
Akikusa, J | 1 |
Laxer, RM | 1 |
Henes, JC | 2 |
Kanz, L | 2 |
Koetter, I | 2 |
Reinhold-Keller, E | 3 |
Metzler, C | 2 |
Fink, C | 1 |
Lamprecht, P | 2 |
Gross, WL | 3 |
Hellmich, B | 2 |
Jayne, D | 1 |
Fritz, J | 1 |
Koch, S | 1 |
Klein, R | 1 |
Horger, M | 1 |
Risler, T | 1 |
Miehle, N | 1 |
Manger, K | 1 |
Iking-Konert, C | 1 |
de Groot, K | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
A Multicenter Randomized Placebo Controlled Treatment Study of Leflunomide in Polymyalgia Rheumatica[NCT03576794] | Phase 3 | 94 participants (Anticipated) | Interventional | 2019-03-01 | Recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
2 reviews available for leflunomide and Granulomatosis, Wegener's
Article | Year |
---|---|
Hallmark trials in ANCA-associated vasculitis (AAV) for the pediatric rheumatologist.
Topics: Adult; Anti-Inflammatory Agents; Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis; Azathio | 2019 |
Advances in the therapy of Wegener's granulomatosis.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Azathioprine; Cyclophosphamide; Etan | 2006 |
2 trials available for leflunomide and Granulomatosis, Wegener's
Article | Year |
---|---|
Maintenance of remission with leflunomide in Wegener's granulomatosis.
Topics: Adult; Aged; Antirheumatic Agents; Drug Therapy, Combination; Female; Glucocorticoids; Granulomatosi | 2004 |
Elevated relapse rate under oral methotrexate versus leflunomide for maintenance of remission in Wegener's granulomatosis.
Topics: Administration, Oral; Adult; Aged; Antibodies, Antineutrophil Cytoplasmic; C-Reactive Protein; Cyclo | 2007 |
4 other studies available for leflunomide and Granulomatosis, Wegener's
Article | Year |
---|---|
Rituximab and leflunomide for Wegener's granulomatosis: a long-term follow-up.
Topics: Antibodies, Monoclonal, Murine-Derived; Antirheumatic Agents; Follow-Up Studies; Granulomatosis with | 2011 |
[How long should cyclophosphamide therapy of Wegener's granulomatosis continue?].
Topics: Adjuvants, Immunologic; Administration, Oral; Anti-Infective Agents; Anti-Inflammatory Agents; Anti- | 2002 |
Leflunomide versus methotrexate in Wegener's granulomatosis.
Topics: Glucocorticoids; Granulomatosis with Polyangiitis; Humans; Immunosuppressive Agents; Isoxazoles; Lef | 2007 |
Rituximab for treatment-resistant extensive Wegener's granulomatosis--additive effects of a maintenance treatment with leflunomide.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antibodies, Monoclonal | 2007 |